查看購物車
  • Japanese
  • Korean
視網膜疾病模型（2026）：各國疾病盛行率數據
市場調查報告書
商品編碼
2126254

視網膜疾病模型（2026）：各國疾病盛行率數據

2026 Retinal Disease Model: Country-Level Disease Prevalence Data
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

概述：

Market Scope 的「視網膜疾病模型（2026）」提供了全球視網膜疾病實際規模的詳細國別分析。該模型包括所有人口超過 100 萬的國家/地區按年齡層分類的詳細盛行率估計和預測。

該專有模型基於最新的臨床研究和全球人口預測，對視網膜疾病進行了嚴謹且前瞻性的分析，並可根據地區和疾病類別進行客製化，以滿足特定的戰略需求。透過此模型，企業可以量化地了解目標患者群體，評估臨床和商業化產品的目標市場，並掌握疾病發生率和人口趨勢的演變方向。

調查方法：

Market Scope 利用其專有的人口統計模型和最新的臨床研究，估算各國疾病盛行率。視網膜疾病模型整合了 130 多項同行評審的臨床和流行病學研究的數據，每項輸入數據都經過仔細評估，並根據研究設計、樣本大小、年齡分組、地理相關性和調查範圍進行加權。然後，將這些數據與特定國家的人口結構和人口預測進行匹配，從而產生跨市場的一致且可比較的盛行率估算值。

目錄

「視網膜疾病模型（2026）」提供了228個人口超過百萬的國家/地區按年齡層分類的全面國家/地區特定發病率數據，涵蓋了全球視網膜疾病的全部負擔。其範圍從商業性意義的大規模疾病到罕見遺傳性疾病，為當前市場和未來治療研發相關的患者群體提供了統一的視角。

涵蓋的疾病如下：

  • 老齡化黃斑部病變：早期AMD、晚期AMD、滲出性AMD和地圖狀萎縮
  • 糖尿病視網膜疾病：非增殖性糖尿病視網膜病變（輕度、中度和重度）、增殖性糖尿病視網膜病變（伴隨或不伴隨糖尿病黃斑部水腫）、糖尿病黃斑部水腫和伴隨視力障礙的糖尿病視網膜病變。
  • 視網膜血管疾病：中央視網膜靜脈阻塞與視網膜分支靜脈阻塞症
  • 其他視網膜疾病：近視性脈絡膜新生血管、非感染性後葡萄膜炎、視網膜剝離、視網膜裂孔、視網膜裂孔
  • 遺傳性視網膜疾病：視網膜色素變性、斯特格氏黃斑失養症、脈絡膜萊伯氏先天性黑朦症、Leber遺傳性視神經病變、全色盲、X連鎖青少年視網膜劈裂症及其他遺傳性視網膜疾病。
簡介目錄

Description:

Market Scope’s "2026 Retinal Disease Model" delivers deep, country-level insight into the true scale of retinal disease worldwide, with detailed prevalence estimates and five-year forecasts by age group for every country with a population over one million.

Built on the latest clinical research and global demographic projections, this proprietary model provides a rigorous, forward-looking view of retinal disease—and can be customized by geography and disease category to match specific strategic needs. The model enables companies to quantify addressable patient populations, evaluate target markets for clinical- and commercial-stage products, and understand how disease volume and demographics are expected to evolve over time.

Methodology:

Market Scope utilizes proprietary demographic models and the latest clinical research to estimate diseased populations at the country level. The retinal disease model integrates data from more than 130 peer-reviewed clinical and epidemiologic studies, with each input carefully evaluated and weighted based on study design, sample size, age stratification, geographic relevance, and scope. These data are then aligned with country-specific population structures and demographic projections to produce consistent, comparable prevalence estimates across markets

Table of Contents

The "2026 Retinal Disease Model" provides comprehensive, country-level prevalence data by age group across 228 countries with populations over one million, capturing the full global burden of retinal disease. Coverage spans large, commercially significant indications as well as rare inherited conditions, giving a unified view of patient populations relevant to both current markets and future therapeutic development.

Conditions covered include:

  • Age-related macular degeneration: early AMD, late AMD, wet AMD, and geographic atrophy
  • Diabetic retinal disease: non-proliferative DR (mild, moderate, severe), proliferative DR (with and without DME), diabetic macular edema, and vision-threatening DR
  • Retinal vascular disorders: central and branch retinal vein occlusion
  • Other retinal conditions: myopic choroidal neovascularization, non-infectious posterior uveitis, retinal detachment, retinal holes, and tears
  • Inherited retinal diseases: retinitis pigmentosa, Stargardt disease, choroideremia, Leber congenital amaurosis, Leber hereditary optic neuropathy, achromatopsia, X-linked juvenile retinoschisis, and other IRDs